Patents Examined by Fred H Reynolds
  • De novo design of protein switches
    Patent number: 10851135
    Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: December 1, 2020
    Assignee: University of Washington
    Inventors: Robert A. Langan, Scott Boyken, David Baker, Walter Novak, Marc Joseph Lajoie, Alfredo Quijano Rubio
  • Immunogenic compound
    Patent number: 10849984
    Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 1, 2020
    Assignee: Altimmune UK Limited
    Inventor: Bertrand Georges
  • Supramolecular hydrogels containing angiotensin receptor blockers for targeted treatment of diabetic wounds
    Patent number: 10835615
    Abstract: The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: November 17, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Honggang Cui, Jeremy D. Walston, Peter M. Abadir, Ran Lin
  • Anti-tumor peptides and use thereof
    Patent number: 10829523
    Abstract: The anti-tumor peptide provided by the present invention is a synthetic peptide having both amino acid sequences represented by the following (1) and (2): (1) an amino acid sequence constituting the transmembrane domain of transmembrane protein 141 (TMEM 141), or a modified amino acid sequence having deletion, replacement, or addition of one, two, or three amino acid residues of the amino acid sequence; and (2) an amino acid sequence functioning as a cell membrane penetrating peptide (CPP).
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 10, 2020
    Assignees: Keio University, National University Corporation Nagoya, Toagosei Co., Ltd.
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada, Jun Kudoh, Tamami Adachi, Yasuhiro Tonoyama
  • Multifunctionalized bioactive polycaprolactone
    Patent number: 10828371
    Abstract: A multifunctionalized polycaprolactone polymer, a process for forming a multifunctionalized polycaprolactone polymer, and an article of manufacture comprising a material containing a multifunctionalized polycaprolactone polymer are disclosed. The multifunctionalized polycaprolactone polymer includes at least two functional groups. The process of forming the multifunctionalized polycaprolactone polymer includes forming a caprolactone monomer having at least two functional groups, and polymerizing the caprolactone monomer. Further, the article of manufacture includes a polycaprolactone polymer having at least two functional groups.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: November 10, 2020
    Assignee: International Business Machines Corporation
    Inventors: Eric J. Campbell, Sarah K. Czaplewski-Campbell, Brandon M. Kobilka, Jason T. Wertz
  • Macrocyclic compounds and methods of making and using same
    Patent number: 10781234
    Abstract: Provided are macrocyclic compounds having one or more transmembrane segment-thermoresponsive segment moiety. Also provided are dimers comprising two macrocyclic units, which have one or more transmembrane segment-thermoresponsive segment moiety, joined by one or more crosslinking moieties. The macrocyclic compounds and macrocyclic units have a macrocyclic backbone comprise alternating alpha amino acid and meta-aminobenzoic acid moieties. The macrocyclic compounds and dimers can be used to deliver a cargo (e.g., cell-interacting agents such as, for example, drugs and cryoprotectants) to, for example, an organ, tissue, or an individual, A cargo may be encapsulated in lipid vesicles.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: September 22, 2020
    Assignee: The Research Foundation for The State University of New York
    Inventor: Bing Gong
  • Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof
    Patent number: 10781241
    Abstract: The present invention relates to providing improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. Preferably, the iCP-SOCS3 recombinant protein may be used as protein-based anti-pancreatic cancer agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: September 22, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Cell-permeable bone morphogenetic protein (CP-BMP) recombinant protein and use thereof
    Patent number: 10774123
    Abstract: The present invention provides the CP-BMP recombinant protein with technical advantages as an intracellular protein therapy for the treatment of bone defects caused by osteogenesis imperfecta, osteoporosis, fracture and osteoctomy in that it could resolve cell-/tissue-permeability and bio-transfer function.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 15, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Polymeric forms of H-NOX proteins
    Patent number: 10766947
    Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 8, 2020
    Assignee: Omniox, Inc.
    Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
  • Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10765726
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 8, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • Vasopressin-2 receptor agonists
    Patent number: 10745443
    Abstract: Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: August 18, 2020
    Assignee: FERRING B.V.
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Pierre Riviere
  • Peptide with anti-obesity and anti-diabetes activity and use thereof
    Patent number: 10738081
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 11, 2020
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Proteasome modulation for treatment of corneal disorders
    Patent number: 10736934
    Abstract: Disclosed herein are methods and compositions useful for preventing or reducing corneal haze of opacification resulting from Limbal Stem Cell Deficiency (LSCD). The invention comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. The invention also comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. In addition, the invention comprises a method of administering to a subject suffering from corneal opacification with a sufficient amount of proteasome modulator, resulting in reduction of Keratin proteins in the cornea of the subject.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: August 11, 2020
    Assignee: The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Inventor: Fawzia Bardag-Gorce
  • Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
    Patent number: 10729741
    Abstract: A treatment window for the intravenous treatment of wounds, including thermal and chemical burns, with cP12 is presented. In particular, Applicants have unexpectedly found that delaying intravenous treatment with fibronectin-derived peptides, such as cP12, from 2 to 6 hours, particularly about 4 hours, after wounding, provides superior wound-closing results than treatment at 1 hour or after 8 or more hours.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 4, 2020
    Assignee: NeoMatrix Therapeutics Inc.
    Inventors: Richard August Clark, Fubao Lin
  • Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress syndrome
    Patent number: 10723763
    Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: July 28, 2020
    Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Blake Paterson, Peter Ward, Alessio Fasano
  • Excipients for stabilising viral particles, polypeptides or biological material
    Patent number: 10716859
    Abstract: A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: July 21, 2020
    Assignee: Stabilitech Biopharma Ltd
    Inventors: Jeffrey Drew, David Thomas Woodward, John Bainbridge, Amanda Corteyn
  • Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
    Patent number: 10703778
    Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: July 7, 2020
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Cell-permeable (CP)-? SOCS3 recombinant protein and uses thereof
    Patent number: 10689424
    Abstract: The present invention is related to development of the improved cell-permeable (CP)-?SOCS3 recombinant protein which disrupt the interaction of leptin receptor (ObR) and suppressor of cytokine signaling 3 (SOCS3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: June 23, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Therapeutically active compounds and their methods of use
    Patent number: 10689414
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 23, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Oral octreotide administered in combination with other therapeutic agents
    Patent number: 10682387
    Abstract: This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a selective estrogen receptor modulator (SERM) and/or a 2nd somatostatin receptor ligand (SRL).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 16, 2020
    Assignee: Chiasma, Inc.
    Inventor: Asi Haviv